Drugs / Tritanrix™ HB+Hib
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01098474 Background | Jul 2010 → Apr 2011 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tritanrix HB+Hib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01098474 ↗ |
| Known as | Tritanrix HepB+Hiberix | “Tritanrix™ HepB+Hiberix™ vaccine” NCT01098474 ↗ |
| Modality | Vaccine | “Tritanrix™ HepB+Hiberix™ vaccine” NCT01098474 ↗ |
| Route | Intramuscular | “administered in the anterolateral region of the left thigh” NCT01098474 ↗ |